Medscape looks past the number on the scale at what GLP-1 treatment really involves for patients over the long run.
Recap by typeshit. Full story at Medscape.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
The Democrat & Chronicle lists the affected lot numbers, so anyone using compounded tirzepatide can check their vials.
Sustainable Views argues the food sector is treating GLP-1 drugs as a megatrend without folding the shift into its climate strategy.
Loading…